VTRS logo

Viatris Inc

VTRS

Build a strategy around VTRS

Accountable AI Logo

Viatris Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-12

Snapshot

  • Intangibles of 22.5B are 148% of equity (15.2B) - tangible book value is NEGATIVE (-7.2B), creating material impairment risk[Goodwill and Other Intangible Assets]
  • FCF TTM of 1.6B despite -3.7B net loss - massive non-cash charges masking cash generation ability[Free Cash Flow TTM]
  • Debt/Equity of 0.97 with 14.7B total debt vs 975M cash - net debt of 13.5B is 10x TTM FCF[Total Debt]

Watch Triggers

  • Free Cash Flow TTM: Falls below 1.2B annuallyBelow this level, dividend + debt service becomes unsustainable without asset sales
  • Goodwill and Other Intangible Assets: Additional impairments >1BCould breach debt covenants or force equity raise at distressed valuations
  • Interest Expense TTM: Rises above 550MWould consume >35% of operating cash flow, threatening dividend

Bull Case

Trading at 0.96x P/S and 6.8x P/CF - deep value if FCF sustains. 12% FCF yield funds 4% dividend plus debt reduction.

PS RatioPCF RatioFree Cash Flow TTM

Revenue of 14.1B with 36% gross margin generates durable cash despite net losses - generic drug portfolio provides stability.

Total Revenue TTMGross Margin TTMCash Flow TTM

Bear Case

Net debt of 13.5B is 8.4x EBITDA (if normalized to ~1.6B) - leverage severely constrains strategic flexibility and amplifies risk.

Net DebtTotal DebtInterest Expense TTM

Intangibles 148% of equity with negative tangible book - further impairments could trigger covenant issues or equity dilution.

Goodwill and Other Intangible AssetsTangible Book ValueCommon Stockholders Equity

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
40%

Leverage VTRS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

FCF yield of 12% (1.6B/13.6B market cap) supports debt paydown and dividend sustainability

1-3ymed
  • Stable generic drug cash flows despite patent cliffs
  • Low capex requirements (383M TTM, 2.7% of revenue)
  • Dividend yield ~4% (0.48/share) covered 4x by FCF
FCF TTM 1.6B vs dividend payout 140MCapex/Revenue only 2.7%P/CF ratio 6.8x vs industry median 14.3x

Balance sheet restructuring required - 22.5B intangibles at risk of further writedowns

3-12mhigh
  • EBITDA TTM negative (-599M) after impairments
  • Goodwill 6.7B from Mylan-Upjohn merger
  • Interest expense 472M consuming 30% of operating cash flow
Net loss of 3.7B TTM vs prior profitabilityEBIT -3.4B indicates massive non-cash chargesNegative tangible book value (-7.2B)

Valuation Context

Caveats

Public Strategies Rankings

See how Viatris Inc ranks across different investment strategies.

Leverage VTRS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.